Mereo BioPharma Group/$MREO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Primary listing
Employees
36
Headquarters
Website
MREO Metrics
BasicAdvanced
$305M
-
-$0.32
0.42
-
Price and volume
Market cap
$305M
Beta
0.42
52-week high
$4.23
52-week low
$1.47
Average daily volume
1.5M
Financial strength
Current ratio
8.128
Quick ratio
7.923
Total debt to equity
1.109
Interest coverage (TTM)
-47.82%
Profitability
EBITDA (TTM)
-44.01
Gross margin (TTM)
73.60%
Net profit margin (TTM)
-9,909.60%
Operating margin (TTM)
-8,923.40%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-35.13%
Return on equity (TTM)
-74.61%
Valuation
Price to revenue (TTM)
601.692
Price to book
5.63
Price to tangible book (TTM)
5.68
Price to free cash flow (TTM)
-9.051
Free cash flow yield (TTM)
-11.05%
Free cash flow per share (TTM)
-0.212
Growth
Revenue change (TTM)
-50.00%
Earnings per share change (TTM)
20.07%
3-year earnings per share growth (CAGR)
-13.65%
What the Analysts think about MREO
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
Bulls say / Bears say
Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track with a second interim analysis expected in mid-2025 and a final readout in Q4 2025, demonstrating steady clinical progress.
Mereo held $62.5 million in cash as of March 31, 2025, providing funding runway into 2027 and supporting ongoing development programs.
Alvelestat received Orphan Designation from the European Commission for the treatment of AATD-LD in Q1 2025, reinforcing regulatory exclusivity and attractiveness to potential partners.
Mereo’s shares plunged 33.7% on July 10, 2025, after the Phase 3 Orbit trial did not meet criteria for early termination at the second interim analysis, reflecting investor concern over efficacy thresholds.
The stock has declined 51.14% year-to-date as of early October 2025, underscoring sustained market skepticism toward its pipeline execution.
Total R&D expenses rose to $20.9 million in 2024, up from $17.4 million in 2023, increasing cash burn ahead of potential revenue inflection points.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MREO Financial Performance
Revenues and expenses
MREO Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $305M as of October 31, 2025.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of October 31, 2025.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of October 31, 2025.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.